Michael Sweeney

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Richard J. Mills, Sean J. Humphrey, Patrick R.J. Fortuna et al. · Cell · 2021 · 233 citations · Full text

Medicine, Cardiology, Infectious Diseases +12

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes

Kausik K. Ray, Stephen J. Nicholls, Kevin A. Buhr et al. · JAMA · 2020 · 164 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

Laura Tsujikawa, Li Fu, Shovon Das et al. · Clinical Epigenetics · 2019 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease

Stephen J. Nicholls, Kausik K. Ray, Jan O. Johansson et al. · American Journal of Cardiovascular Drugs · 2017 · 125 citations

Medicine, Cardiology, Pharmacology +15

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

Dean Gilham, Sylwia Wasiak, Laura Tsujikawa et al. · Atherosclerosis · 2016 · 112 citations · Full text

Medicine, Molecular Biology, Pharmacology +17